3176-63-4

Basic information

• Product Name: 4-METHYL (1H)INDAZOLE
• Synonyms: 4-METHYL (1H)INDAZOLE;4-METHYLINDAZOLE;1H-Indazole, 4-methyl-;4-methyl-1H-indazole(SALTDATA: FREE)
• CAS NO: 3176-63-4
• Molecular Formula: C₈H₈N₂
• Molecular Weight: 132.16
• Mol File: 3176-63-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 114-116℃
• Boiling Point: 285.1 °C at 760 mmHg
• Flash Point: 133.3 °C
• Appearance: /
• Density: 1.186 g/cm³
• Vapor Pressure: 0.00491mmHg at 25°C
• Refractive Index: 1.666
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.47±0.40(Predicted)
• CAS DataBase Reference: 4-METHYL (1H)INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHYL (1H)INDAZOLE(3176-63-4)
• EPA Substance Registry System: 4-METHYL (1H)INDAZOLE(3176-63-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 3176-63-4(Hazardous Substances Data)

Usage

General Description

4-Methyl (1H)indazole is a chemical compound belonging to the indazole family, which is widely used in the pharmaceutical and research industries. It is a substituted indazole derivative with a methyl group attached to the fourth position of the indazole ring. This chemical exhibits a wide range of biological activities, including anti-inflammatory, analgesic, and antipyretic effects. It has also been studied for its potential in treating various central nervous system disorders, such as neurodegenerative diseases and psychiatric disorders. Additionally, 4-Methyl (1H)indazole has been explored for its potential as a building block in the synthesis of new pharmaceutical compounds with improved therapeutic properties. Due to its diverse pharmacological activities and promising potential, this chemical continues to be the focus of ongoing research and development efforts.

InChI:InChI=1/C8H8N2/c1-6-3-2-4-8-7(6)5-9-10-8/h2-5H,1H3,(H,9,10)

Upstream product

• 83-41-0 2,3-dimethylnitrobenzene 
• 95-52-3 2-Fluorotoluene 
• 87-59-2 2,3-Dimethylaniline 

Downstream Products

• 1438463-93-4 C₁₄H₁₁N₃O₂ 
• 1330064-48-6 C₂₂H₁₆ClF₃N₄O 
• 1330064-82-8 C₁₄H₁₃N₃ 
• 1352415-05-4 methyl 4-methyl-1H-indazole-3-carboxylate 
• 885522-63-4 3-iodo-4-methyl-1H-indazole 
• 1034874-85-5 2-amino-4-methylindazole 
• 33334-10-0 1-amino-3-phenylindazole 
• 860007-80-3 4-methyl-1-(4-trifluoromethylphenyl)-1H-indazole 

Relevant articles and documents

Inhibition of the Cysteine Protease Human Cathepsin L by Triazine Nitriles: Amide???Heteroarene π-Stacking Interactions and Chalcogen Bonding in the S3 Pocket

We report an extensive “heteroarene scan” of triazine nitrile ligands of the cysteine protease human cathepsin L (hCatL) to investigate π-stacking on the peptide amide bond Gly67–Gly68 at the entrance of the S3 pocket. This heteroarene???peptide bond stacking was supported by a co-crystal structure of an imidazopyridine ligand with hCatL. Inhibitory constants (Ki) are strongly influenced by the diverse nature of the heterocycles and specific interactions with the local environment of the S3 pocket. Binding affinities vary by three orders of magnitude. All heteroaromatic ligands feature enhanced binding by comparison with hydrocarbon analogues. Predicted energetic contributions from the orientation of the local dipole moments of heteroarene and peptide bond could not be confirmed. Binding of benzothienyl (Ki=4 nm) and benzothiazolyl (Ki=17 nm) ligands was enhanced by intermolecular C?S???O=C interactions (chalcogen bonding) with the backbone C=O of Asn66 in the S3 pocket. The ligands were also tested for the related enzyme rhodesain.

BICYCLIC DERIVATIVES AS PPAR MODULATORS

The present invention is directed to compounds represented by the following structural formula, Formula (I), and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) R2 is selected from the group consisting of C0-C8 alkyl and C1-4- heteroalkyl; (b) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (c) U is an aliphatic linker wherein one carbon atom of the aliphatic linker is optionally replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with from one to four substituents each independently selected from R30; (d) Y is selected from the group consisting of C, O, S, NH and a single bond; and (e) E is C(R3)(R4)A or A.

A Novel Approach to 1H-Indazoles via Arylazosulfides

Treatment of variously substituted (o-alkylaryl)azosulfides 1a-n with potassium tert-butoxide in DMSO at room temperature smoothly furnishes 1H-indazoles 2a-n.